Science is fun


Rekom Biotech receives a special mention in the XII Awards for Excellence in Andalusian SMEs


XII Awards for Excellence in Andalusian SMEs

The Awards for Excellence in Andalusian SMEs, organized by Caixabank and Grupo Joly, were created to give visibility to the reality that Andalusia has an excellent network of SMEs and, in many cases, they are leaders in their sector and are completely focused on the international market.


View more


Rekom Biotech is listed as one of the top ten leading vendors in the Insight Partners' Viral Antigens Market Forecast to 2027 report


The Insight Partners makes reports that provide in-depth analysis on the selected topic, making a review of the most important companies in the sector, and restraints and opportunities available in the market.

The Viral Antigens Market Forecast to 2027 report provides a study of Viral Antigens market using SWOT analysis (Strength, Weakness, Opportunities and Threat to the organization), and also provides an in-depth survey of the key players in the market. This survey is based on various objectives of an organization, such as profiling, the product outline, the quantity of production, required raw material, and the financial health of the organization. Rekom Biotech appears as one of the ten top leading vendors of the Viral Antigens market.


View more


Rekom Biotech's antigen for COVID-19 is ready to support India for rapid and effective detection of this disease


On this critical COVID-19 pandemic times, each social agent must give its best and show social commitment. Our best way to support the health world in this situation is with our recombinant nucleoprotein antigen for SARS-CoV (NP-CTD), the most trustable method for a fast and effective COVID-19 early detection.

We are happy to announce that Rekom Biotech will be a supplier of raw material for COVID-19 detection to the Indian company whose Covid IgG ELISA kit is approved by the Indian government.

Rekom Biotech has been awarded with a grant from CDTI for its R&D and investment project of COVID-19


The Spanish Centre for the Development of Industrial Technology (CDTI) has chosen to award a grant to R&D and investment projects in order to face the health emergency declared due to COVID-19. The selected projects allow the following: increase the availability of emergency products; contribute to improve the treatment of the disease, as well as the diagnosis and clinical management of patients infected by SARS-CoV-2; contribute to the design, development and implementation of public health measures to respond effectively to the epidemic.

The total amount of projects presented reached the number of 577 and only 9 of them were selected, including Rekom Biotech's one - "PREPARATION OF BIOMARKERS FOR DETECTION OF COVID-19 AND FOR USE IN RAPID TESTS TO MEASURE SEROPREVALENCE IN THE POPULATION".


View more

REKOM BIOTECH signs a China distribution agreement


Rekom Biotech and Ambigen have closed an exclusive distribution agreement on August 28th, 2020, for the commercialization of Rekom products in China.

China represents one of the largest in vitro diagnostics markets in the Asia-Pacific region and this trend is expected to continue over the forecast period. For Rekom Biotech it would be an honor to be able to offer high quality raw material to all these IVD test manufacturers that are in search of the best product for their assays. We are confident that our partnership with Ambigen will provide our chinese customers with an outstanding quality and exceptional customer service including pre and post-sale support, guaranteeing the best possible experience.